# Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations

> **NCT07707817** · NA · RECRUITING · sponsor: **Uwemedimo Friday Ekpo** · enrollment: 5760 (estimated)

## Conditions studied

- Onchocerciasis (River Blindness)
- Schistosomiasis
- Soil Transmitted Helminth (STH) Infections
- Lymphatic Filariasis

## Interventions

- **OTHER:** Modified Mass Administration of Medicines Strategy
- **DRUG:** Albendazole 400 mg
- **DRUG:** Praziquantel 40 mg/kg
- **DRUG:** Ivermectin
- **DRUG:** Ivermectin + albendazole

## Key facts

- **NCT ID:** NCT07707817
- **Lead sponsor:** Uwemedimo Friday Ekpo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 5760 (ESTIMATED)
- **Last updated:** 2026-07-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707817, "Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*